| Apolipoprotein AI exerts bactericidal activity against Yersinia enterocolitica serotype O: 3 M Biedzka-Sarek, J Metso, A Kateifides, T Meri, TS Jokiranta, A Muszyński, ... Journal of Biological Chemistry 286 (44), 38211-38219, 2011 | 49 | 2011 |
| Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels CL Haase, R Frikke‐Schmidt, BG Nordestgaard, AK Kateifides, ... Journal of internal medicine 270 (2), 136-146, 2011 | 49 | 2011 |
| ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT A Duka, P Fotakis, D Georgiadou, A Kateifides, K Tzavlaki, ... Journal of lipid research 54 (1), 107-115, 2013 | 47 | 2013 |
| Carboxyl terminus of apolipoprotein AI (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells PM Ohnsorg, L Rohrer, D Perisa, A Kateifides, A Chroni, D Kardassis, ... Journal of Biological Chemistry 286 (10), 7744-7754, 2011 | 36 | 2011 |
| Role of the hydrophobic and charged residues in the 218–226 region of apoA-I in the biogenesis of HDL P Fotakis, AK Kateifides, C Gkolfinopoulou, D Georgiadou, M Beck, ... Journal of lipid research 54 (12), 3281-3292, 2013 | 18 | 2013 |
| Significance of the hydrophobic residues 225–230 of apoA-I for the biogenesis of HDL1 [S] P Fotakis, I Tiniakou, AK Kateifides, C Gkolfinopoulou, A Chroni, ... Journal of lipid research 54 (12), 3293-3302, 2013 | 17 | 2013 |
| Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans G Samonis, S Maraki, K Leventakos, AM Spanaki, A Kateifidis, ... Medical mycology 44 (3), 233-235, 2006 | 17 | 2006 |
| Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL AK Kateifides, IN Gorshkova, A Duka, A Chroni, D Kardassis, VI Zannis Journal of Lipid Research 52 (7), 1363-1372, 2011 | 15 | 2011 |
| Pleiotropic functions of HDL lead to protection from atherosclerosis and other diseases V Zannis, A Kateifides, P Fotakis, E Zanni, D Kardassis Dyslipidemia-From Prevention to Treatment, 173-96, 2012 | 12 | 2012 |
| Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial R Lafayette, J Tumlin, R Fenoglio, J Kaufeld, MAP Valdivia, MS Wu, ... Journal of the American Society of Nephrology, 10.1681, 2025 | 7 | 2025 |
| WCN23-0140 a phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin a (Iga) nephropathy or proliferative lupus nephritis (Ln) A Kateifides, K Garlo, K Rice, N Spoerri, N Najafian Kidney International Reports 8 (3), S54-S55, 2023 | 2 | 2023 |
| # 145 Subgroup and secondary endpoint evaluation of a phase 2 randomized placebo-controlled trial of ravulizumab in IgA nephropathy MÁP Valdivia, JA Tumlin, J Kaufeld, MS Wu, R Lafayette, J Barratt, ... Nephrology Dialysis Transplantation 39 (Supplement_1), gfae069-0434-145, 2024 | 1 | 2024 |
| # 1021 A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy H Trimarchi, J Barratt, HL Heerspink, L Inker, A Bruchfeld, H Zhang, ... Nephrology Dialysis Transplantation 39 (Supplement_1), gfae069-0444-1021, 2024 | 1 | 2024 |
| Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial: FR-OR60 JA Tumlin, RA Lafayette, J Barratt, MS Wu, SG Kim, JK Kaufeld, ... Journal of the American Society of Nephrology 35 (10S), 10.1681, 2024 | | 2024 |
| Mutation in APOA1 predicts increased risk of ischaemic heart disease and mortality without low HDL cholesterol CL Haase, R Frikke-Schmidt, BG Nordestgaard, AK Kateifides, ... Amyloid 17, 129, 2010 | | 2010 |
| 119 MUTATION IN APOAI PREDICTS INCREASED RISK OF ISCHEMIC HEART DISEASE AND EARLY DEATH WITHOUT LOW HDL CHOLESTEROL C Lundegaard, R Frikke-Schmidt, B Nordestgaard, A Kateifides, ... Atherosclerosis Supplements 10 (2), e235, 2009 | | 2009 |
| Resequencing APOAI Identifies Common Mutation that Predicts Increased Risk of Ischemic Heart Disease and Decreased Longevity without Dyslipidemia C Lundegaard, R Frikke-Schmidt, BG Nordestgaard, AK Kateifides, ... Circulation 118 (suppl_18), S_955-S_955, 2008 | | 2008 |
| A Phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin A nephropathy or proliferative lupus nephritis (LN) A Kateifides, K Garlo, K Rice, N Spoerri, N Najafian | | |
Panagiotis FotakisDren BioVahvistettu sähköpostiosoite verkkotunnuksessa drenbio.com